Pallidal neuromodulation of the explore/exploit trade-off in decision-making

  1. Ana Luisa de A. Marcelino
  2. Owen Gray
  3. Bassam Al-Fatly
  4. William Gilmour
  5. J Douglas Steele
  6. Andrea A Kühn
  7. Tom Gilbertson  Is a corresponding author
  1. Charité - Universitätsmedizin Berlin, Germany
  2. University of Dundee, United Kingdom

Abstract

Every decision that we make involves a conflict between exploiting our current knowledge of an action's value or exploring alternative courses of action that might lead to a better, or worse outcome. The sub-cortical nuclei that make up the basal ganglia have been proposed as a neural circuit that may contribute to resolving this explore-exploit 'dilemma'. To test this hypothesis, we examined the effects of neuromodulating the basal ganglia's output nucleus, the globus pallidus interna, in patients who had undergone deep brain stimulation (DBS) for isolated dystonia. Neuromodulation enhanced the number of exploratory choices to the lower value option in a 2-armed bandit probabilistic reversal-learning task. Enhanced exploration was explained by a reduction in the rate of evidence accumulation (drift rate) in a reinforcement learning drift diffusion model. We estimated the functional connectivity profile between the stimulating DBS electrode and the rest of the brain using a normative functional connectome derived from heathy controls. Variation in the extent of neuromodulation induced exploration between patients was associated with functional connectivity from the stimulation electrode site to a distributed brain functional network. We conclude that the basal ganglia's output nucleus, the globus pallidus interna, can adaptively modify decision choice when faced with the dilemma to explore or exploit.

Data availability

Raw choice and reaction time data, computational model parameter estimates, simulated data and r-maps from connectivity analysis are available via the Open Science Framework https://osf.io/fs36g/

The following data sets were generated

Article and author information

Author details

  1. Ana Luisa de A. Marcelino

    Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3291-7222
  2. Owen Gray

    Division of Imaging Science and Technology, University of Dundee, Dundee, United Kingdom
    Competing interests
    No competing interests declared.
  3. Bassam Al-Fatly

    Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0067-6177
  4. William Gilmour

    Division of Imaging Science and Technology, University of Dundee, Dundee, United Kingdom
    Competing interests
    No competing interests declared.
  5. J Douglas Steele

    Division of Imaging Science and Technology, University of Dundee, Dundee, United Kingdom
    Competing interests
    No competing interests declared.
  6. Andrea A Kühn

    Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
    Competing interests
    Andrea A Kühn, has received from honoraria from Boston Scientific, Medtronic and Teva..
  7. Tom Gilbertson

    Division of Imaging Science and Technology, University of Dundee, Dundee, United Kingdom
    For correspondence
    tgilbertson@dundee.ac.uk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9866-1565

Funding

Chief Scientist Office

  • Tom Gilbertson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The which was approved by the local ethics committee (Charité - Universitätsmedizin Berlin, EA1/179/20).

Copyright

© 2023, de A. Marcelino et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,215
    views
  • 198
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ana Luisa de A. Marcelino
  2. Owen Gray
  3. Bassam Al-Fatly
  4. William Gilmour
  5. J Douglas Steele
  6. Andrea A Kühn
  7. Tom Gilbertson
(2023)
Pallidal neuromodulation of the explore/exploit trade-off in decision-making
eLife 12:e79642.
https://doi.org/10.7554/eLife.79642

Share this article

https://doi.org/10.7554/eLife.79642

Further reading

    1. Neuroscience
    François Kroll, Joshua Donnelly ... Jason Rihel
    Research Article

    By exposing genes associated with disease, genomic studies provide hundreds of starting points that should lead to druggable processes. However, our ability to systematically translate these genomic findings into biological pathways remains limited. Here, we combine rapid loss-of-function mutagenesis of Alzheimer’s risk genes and behavioural pharmacology in zebrafish to predict disrupted processes and candidate therapeutics. FramebyFrame, our expanded package for the analysis of larval behaviours, revealed that decreased night-time sleep was common to F0 knockouts of all four late-onset Alzheimer’s risk genes tested. We developed an online tool, ZOLTAR, which compares any behavioural fingerprint to a library of fingerprints from larvae treated with 3677 compounds. ZOLTAR successfully predicted that sorl1 mutants have disrupted serotonin signalling and identified betamethasone as a drug which normalises the excessive day-time sleep of presenilin-2 knockout larvae with minimal side effects. Predictive behavioural pharmacology offers a general framework to rapidly link disease-associated genes to druggable pathways.

    1. Neuroscience
    Kaspar E Vogt, Ashwinikumar Kulkarni ... Robert W Greene
    Research Article

    Sleep loss increases AMPA-synaptic strength and number in the neocortex. However, this is only part of the synaptic sleep loss response. We report an increased AMPA/NMDA EPSC ratio in frontal-cortical pyramidal neurons of layers 2–3. Silent synapses are absent, decreasing the plastic potential to convert silent NMDA to active AMPA synapses. These sleep loss changes are recovered by sleep. Sleep genes are enriched for synaptic shaping cellular components controlling glutamate synapse phenotype, overlap with autism risk genes, and are primarily observed in excitatory pyramidal neurons projecting intra-telencephalically. These genes are enriched with genes controlled by the transcription factor, MEF2c, and its repressor, HDAC4. Sleep genes can thus provide a framework within which motor learning and training occur mediated by the sleep-dependent oscillation of glutamate-synaptic phenotypes.